Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07276074

Acronym

EPPATHUS

Enrollment

160

Registered

2025-12-10

Start date

2024-12-18

Completion date

2025-12-31

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antithrombinemia

Keywords

Anticoagulants, Antithrombinemia, Extracorporeal membrane oxygenation, Renal replacement therapy, Cardiopulmonary bypass

Brief summary

Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially low-molecular-weight heparin (LMWH). In intensive care, patients are mostly treated with anticoagulants for either preventive or curative purposes, particularly for those whose care requires renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), or cardiopulmonary bypass (CPB). The use of various types of membranes associated with these procedures can lead to degradation of blood proteins (including AT). An imbalance in hemostasis can then occur, resulting in ineffective anticoagulation. At the Strasbourg University Hospitals (HUS), these medications are directly available in the intensive care units, allowing for immediate administration in an emergency. Pharmaceutical and medical analysis is therefore not performed before administration.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult subject (≥18 years old) * Female and male * Having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023.

Exclusion criteria

* Subject (and/or their legal representative, if applicable) having expressed their opposition to the reuse of their data for scientific research purposes * Minor subject

Design outcomes

Primary

Measure	Time frame	Description
Overview of antithrombin prescriptions	Up to 1 year	This is a retrospective study describing antithrombin prescriptions at the Strasbourg University Hospitals over a one-year period (from January 1, 2022 to December 31, 2023)

Countries

France

Contacts

Primary ContactXavier DELABRANCHE, MD

xavier.delabranche@chru-strasbourg.fr33 3 69 55 09 36

Outcome results